SEARCH RESULTS
Your search for "" returned the following 530 results.
BerGenBio Reports Third Quarter 2022 Financial Results and Provides Business Update
- Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients -- Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 mutations -- Strengthened financial position with support from largest shareholder - BERGEN, Norway, November 15, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet…
Read MoreBerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations
- Study will assess bemcentinib in combination with current standard of care for 1st line NSCLC - - Approximately 20% of NSCLC patients have STK11 mutations - - First patient is expected to be dosed in 4Q22 - BERGEN, Norway, October 11, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe…
Read MoreBerGenBio ASA: Invitation to third quarter 2022 results webcast
Bergen, Norway, 8 November 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the third quarter 2022 on Tuesday 15 November 2022. The briefing will take place at 10:00 am CET at:Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslowhere BerGenBio's senior management team will…
Read MoreBERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS
BERGEN, Norway, September 27, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Oslo University Hospital announced today that the first patient has been included in a study of BerGenBio’s oral, highly selective AXL inhibitor, bemcentinib, as part of the EU-SolidAct trial in hospitalized COVID-19 patients. The…
Read More
